secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0001171843-25-003910
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst shareholders approve 11M share increase in stock incentive plan at annual meeting
--------------------------------------------------------------------------------

- Director George Abercrombie retired effective June 12, 2025 after 13 years; no disagreement cited.
- Shareholders approved amended Stock Incentive Plan, increasing shares available by 11,000,000 to 81,090,000 total.
- Advisory say-on-pay passed with 143.1M for vs 6.4M against; auditor Ernst & Young ratified with 174.7M for.
- Director nominees Steven Galson and Alan Levin re-elected with ~146M votes each.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325003910/0001171843-25-003910-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325003910/f8k_061625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-003910

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer